H.C. Wainwright upgraded Fulcrum Therapeutics (FULC) to Buy from Neutral with a price target of $12, up from $4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $15 from $12 at Oppenheimer
- Fulcrum Therapeutics Announces Promising Phase 1b Trial Results
- Fulcrum Therapeutics’ pociredir shows efficacy in sickle cell disease
- Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)
- Fulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs